Basch EM, Deal AM, Dueck AC, et al. Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. J Clin Oncol. 35, 2017 (suppl; abstr LBA2).
Durvalumab met of zonder tremelimumab versus EXTREME bij R/M HNSCC
mrt 2023 | Hoofd-halsoncologie